This transaction was not discretionary, as it was executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) on January 15. The RSUs, granted on February 12, 2024, vest annually over four years, contingent upon continued service with Scholar Rock.Following this transaction, Marantz holds 67,200 shares, consisting of 12,558 shares of common stock and 54,642 RSUs. Analysts maintain price targets ranging from $33 to $57, with InvestingPro subscribers having access to 13 additional key insights about Scholar Rock’s financial health and growth prospects through the comprehensive Pro Research Report. Analysts maintain price targets ranging from $33 to $57, with InvestingPro subscribers having access to 13 additional key insights about Scholar Rock’s financial health and growth prospects through the comprehensive Pro Research Report.
This transaction was not discretionary, as it was executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) on January 15. The RSUs, granted on February 12, 2024, vest annually over four years, contingent upon continued service with Scholar Rock.
Following this transaction, Marantz holds 67,200 shares, consisting of 12,558 shares of common stock and 54,642 RSUs.
In other recent news, Scholar Rock, a biopharmaceutical company, is advancing towards the commercialization of apitegromab, a potential treatment for spinal muscular atrophy (SMA). Regulatory applications are expected to be submitted in the first quarter of 2025, with a U.S. launch anticipated in the fourth quarter of the same year. In addition to SMA, Scholar Rock is also advancing its cardiometabolic program, with topline data from the Phase 2 EMBRAZE trial in obesity expected in the second quarter of 2025. Another candidate, SRK-439, is on track for an Investigational New Drug (IND) application filing in the third quarter of 2025 for obesity treatment.
H.C. Wainwright, Truist Securities, and BMO Capital Markets have all increased their price targets for Scholar Rock following significant developments in its drug trials. These adjustments were based on the anticipated market performance and potential of Scholar Rock’s apitegromab. Furthermore, the company’s financial position is robust, with sufficient funds to support operations and capital expenditure requirements into the fourth quarter of 2026. Scholar Rock maintains a healthy current ratio of 3.88, indicating strong liquidity, while operating with moderate debt levels.
These recent developments highlight Scholar Rock’s consistent efforts to address unmet needs in the medical field, with a U.S. commercial launch of Apitegromab planned for Q4 2025 and the initiation of a placebo-controlled Phase 2 obesity trial expected towards the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.